Market News AIOpen the app

UBS raised its price target for Gilead Sciences to $195 from $175 and still recommends buying the stock.

OpinionRead the original at marketscreener.com
Good for GILD

UBS raised its price estimate for Gilead and kept its Buy rating, supporting a positive view of the shares. The story does not explain the recent company disclosures, so the positive signal comes from the analyst's opinion.

GILD · Gilead Sciences, Inc.

AI read · Good for GILD

The AI's read

This is a more favorable view from UBS, and its Buy rating remains in place. That supports a positive read for Gilead's shares. The story gives no details about the recent company disclosures, so this is an analyst's view, not new proof of stronger results.

Get alerts for GILD

Follow Gilead Sciences, Inc. (GILD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GILD
Free on the App Store and Google Play, or on the web.